1.6 billion dollars!

On December 13, Loxo, an oncology company under Eli Lilly, announced a cooperation with Foghorn.
The two companies will jointly develop and commercialize a selective BRM tumor project in the Foghorn pipeline and another tumor project with an undisclosed target, as well as a Foghorn-based oncology project.
Three other items discovered on the proprietary Gene Traffic Control platform
.

According to the agreement, Eli Lilly will pay US$300 million in advance cash, up to US$1.
3 billion in development and commercialization mileage, and make a US$80 million equity investment in Foghorn
.

The chromatin regulatory system precisely regulates gene expression, among which chromatin remodeling complex and transcription factor (TF) play a central role
.
Mutations or overexpression of the chromatin remodeling complex can lead to abnormal gene expression, while mutations or overexpression of TF can "hijack" the chromatin remodeling complex to the wrong location, and both can cause disease

Foghorn aims to develop new anti-cancer therapies through the chromatin regulation system.
The drug development steps based on the company’s Gene Traffic Control platform include: 1) Target identification and verification: use complex sequencing and calculation tools to determine the correlation of the chromatin regulation system Genetic dependence
.
2) Mass production and detection of relevant target components of the chromatin regulation system

Foghorn has developed a variety of protein degradation agents, enzyme inhibitors, and transcription factor interferers for chromatin remodeling complexes and transcription factors
.

BAF is the most thoroughly studied chromatin remodeling complex
.
Eli Lilly’s cooperation is aimed at the BRM/BRG1 subunit of the BAF complex

FHD-286 is an effective, selective and allosteric small molecule inhibitor of BAF complex BRG1 and BRM subunits
.
It has shown anti-tumor activity in preclinical studies